Table 4.
Studies of hypofractionated stereotactic radiotherapy for large brain metastases
| First author
(reference) |
Year | Patients | Tumor size | Dose/fractions | MTV
(mL) |
MST (months) | LCR at 1 year (%) | RN (%) |
| Ernst-Stecken
(11) |
2006 | 51 | ≥3 mL | 30–35 Gy/5 fr | 6.0 | 11.0 | 76.0 | 39.2 |
| Marginal (90% IDS) | ||||||||
| Kim (12) | 2011 | 98 | ≥5 mL | 36 Gy/6 fr | 5.0 | 7.0 | 71.0 | 0 |
| Marginal (91% IDS) | ||||||||
| Higuchi (13) | 2009 | 43 | ≥10 mL | 30 Gy/3 fr | 17.6 | 8.8 | 75.9 | N/A |
| Marginal (50% IDS) | (mean) | |||||||
| Minniti (14) | 2016 | 289 | ≥2 cm | 27 Gy/3 fr | 12.5 | 13.4 | 73.0 | 8.0 |
| Marginal (80–90% IDS) | ||||||||
| Murai (15) | 2014 | 54 | ≥2.5 cm | 18–30 Gy/3 fr | N/A | 6.0 | 69.0 | 7.4 |
| 21–35 Gy/5 fr | ||||||||
| Fokas (16) | 2012 | 260 | ≥3 cm | 35 Gy/5 fr | N/A | 9.0 | 71–75 | 4.1 |
| 40 Gy/4 fr | ||||||||
| Wegner (17) | 2015 | 36 | ≥3 cm | 24 Gy/3 fr | 15.6 | N/A | 63.0 | 0 |
| Jeong (18) | 2015 | 37 | ≥3 cm | 30 Gy/3 fr | 17.6 | 16.0 | 87.0 | 15.8 |
| 35 Gy/5 fr | ||||||||
| Marginal (80% IDS) | ||||||||
| Current study | 2018 | 45 | ≥2 cm | 35 Gy/5 fr | 19.3 | 14.2 | 64.7 | 4.4 |
| Marginal (90% IDS) |
Fr: fractions, MTV: median target volume, MST: median survival time, LCR: local control rate, RN: radionecrosis, IDS: isodose surface